PA

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Graverand-Gastineau MPHL et al. - The development of symptom modifying OA drug is exploding with a plethora of pain pathways being pursued and multiple candidates in advanced stages of clinical development. Structure modification in OA remains complex with significant development challenges.

Today in Rheumatology...keeping you current

Anemia and the risk of non-vertebral fractures: The Tromsø Study
Osteoporosis International, 12/10/09

The efficacy of calcitriol therapy in the management of bone loss and fractures: A qualitative review
Osteoporosis International, 12/10/09

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-analysis
Osteoporosis International, 12/10/09